tirzepatide obstructive sleep apnea Eli Lilly's gained FDA approval in December 2024 for treating moderate-to-severe in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Tirzepatide is moving beyond weight

Afolabi OK, Aderibigbe FA, Folarin DT, Arinola A, Wusu AD

Book Your Personalized Weight Loss Consultation in NJ Your transformation is possible, and were ready to help you lead the way

Tirzepatide can cause side effects such as: More common Stomach pain Less common Difficulty in breathing or swallowing fast heartbeat gaseous stomach pain heartburn recurrent fever skin itching, rash, or redness stomach fullness swelling of the face, throat, or tongue vomiting yellow eyes or skin Most of our patients who are prescribed Tirzepatide see minimal side effects

Semaglutide is often just one part of a bigger care plan focused on improving overall wellness

The liquid should fill the syringe with no visible air gaps